SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

One Stop Systems, Inc. engages in the design, manufacture, and marketing of computing modules and systems targeting edge deployments. It deals with the design and manufacture of high-performance customized computer and flash arrays, in-flight entertainment, and connectivity and value-added reseller with minimal customization. The company operates through the OSS and OSS Europe segments. One Stop Systems was founded by Stephen D. Cooper and Mark Gunn in 1998 and is headquartered in Escondido, CA.

One Stop Systems Inc

One Stop Systems is seeing significant attention from the investment community due to its strategic positioning in ruggedized edge computing, which is essential for the expanding physical AI, robotics, and defense infrastructure sectors. Discussions are heavily focused on the company's strong contract pipeline, recent earnings performance, and positive momentum from upcoming index inclusion, with many participants viewing it as an under-the-radar player poised to capitalize on the shift of AI workloads beyond traditional data centers.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLAS Life Sciences is surging as investors anticipate a major catalyst from the final survival event in the Phase 3 REGAL trial, with the stock seeing intense volatility driven by a massive short squeeze. Community members are actively debating the timing of a potential buyout and the drug's long-term curative potential, while the tightening liquidity and extreme borrow costs continue to trap short sellers in a high-pressure environment.

Churchill Capital Corp. XI is a blank check company. It was formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The company was founded by Michael Stuart Klein on June 4, 2025 and is headquartered in New York, NY.

Churchill Capital Corp XI - Ordinary Shares - Class A

The community is actively discussing the potential acquisition of Churchill Capital Corp XI following the merger announcement with Agility Robotics, with many investors debating the long-term viability of the robotics sector and comparing the situation to previous SPAC experiences. Bullish sentiment is driven by the company's backing from major tech players, while others remain skeptical, warning of potential volatility and cautioning against post-merger price fluctuations.

ClearPoint Neuro, Inc. engages in the development and commercialization of platforms for performing minimally invasive surgical procedures in the brain and heart. The firm conducts its procedures under direct, intra-procedural magnetic resonance imaging guidance. Its product platform consists of the ClearPoint system and ClearTrace system. The company was founded by Paul A. Bottomley on March 12, 1998 and is headquartered in Solana Beach, CA.

ClearPoint Neuro Inc

ClearPoint Neuro is trending as investors react to a significant robotic neuro-navigation system development and continued positive momentum from its gene therapy delivery platform. The community is actively debating the company's valuation versus its potential as a 'picks and shovels' play in the neuro-tech sector, with many focused on how the stock will perform given its high short interest and speculative growth profile.

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Johnson & Johnson

Johnson & Johnson is experiencing a significant defensive rotation as market capital pivots from high-beta technology and AI toward established healthcare stalwarts with visible cash flows. The stock's positive performance is further bolstered by institutional confidence in its oncology pipeline, a fresh dividend hike, and active speculation regarding the potential sale of its multi-billion dollar orthopedics division.

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products include diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly on May 10, 1876 and is headquartered in Indianapolis, IN.

Lilly(Eli) & Co

Eli Lilly is trending as a top healthcare leader due to groundbreaking Phase 3 clinical data for its obesity and diabetes pipeline, which has ignited investor excitement regarding its long-term growth prospects. The community is actively discussing this news, alongside broader market rotation into defensive, high-quality pharmaceutical names as participants look to balance their portfolios.

AXT, Inc. engages in the design, development, manufacture and distribution of compound and single element semiconductor substrates. It also sells specialty material substrates and raw materials used to make substrates and other related products. The company was founded by Morris S. Young and Davis Zhang in 1986 and is headquartered in Fremont, CA.

AXT Inc

AXT Inc. is trending as investors debate whether the recent volatility represents a healthy consolidation phase or a deeper structural correction within the AI hardware supply chain. The community is focused on the critical role of Indium Phosphide (InP) substrates as a production bottleneck for high-speed AI optical networking, with ongoing discussions centered on whether recent price fluctuations offer an accumulation window or signal potential downside risks.

Ambarella, Inc. engages in the development of low-power system-on-a-chip (SoC), semiconductors, and software for edge artificial intelligence (AI) applications and intelligent automation. The firm's products include video security, advanced driver assistance (ADAS), electronic mirror, drive recorder, driver or cabin monitoring, autonomous driving, and other robotics applications. It operates through the following geographical segments: Taiwan, Asia Pacific, Europe, North America, and United States. The company was founded by Feng Ming Wang and Leslie D. Kohn on January 15, 2004 and is headquartered in Santa Clara, CA.

Ambarella Inc

Ambarella is seeing significant investor attention following reports that the company is working with bankers to explore strategic options, including a potential sale. The community is actively discussing the implications of this M&A speculation, with many highlighting its long-term potential as a key enabler in the edge AI and robotics hardware supply chain.

Onyx is an infrastructure for a multi-asset, scalable, and cryptographically secure ledger. Onyx functions as a blockchain-based technology that enhances financial ecosystems by enabling a more efficient and interconnected economy, with a mission to develop cryptographic ledgers that optimize security, scalability, and usability. XCN is native to the Onyx XCN Ledger Blockchain as well as the Onyx Goliath Blockchain. XCN is also used as an ERC-20 token for Staking and Governance.

Onyxcoin

Onyxcoin is seeing heightened market activity and community speculation as traders anticipate the launch of its Goliath mainnet. While some community members are bullish on the project's institutional potential and infrastructure goals, others remain highly skeptical, citing ongoing concerns about project transparency and historical price volatility.

Oscar Health, Inc. is a healthcare insurance company, which serves its customers through a technology platform. It offers individual and family, small group and medicare advantage plans, and technology platform to others within the provider and payor space. The company was founded by Mario Tobias Schlosser, Kevin Nazemi, and Joshua Kushner on October 25, 2012 and is headquartered in New York, NY.

Oscar Health Inc - Ordinary Shares - Class A

Oscar Health is trending as strong institutional demand and positive earnings sentiment drive a breakout, with the community closely tracking the stock's ability to maintain momentum above critical psychological resistance levels. Investors are focused on the company's shifting narrative from turnaround risk to durable growth and margin expansion, often highlighting management's significant share ownership as a key indicator of long-term conviction.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

PCS Software Integrates Triumph Market Rate Intelligence Directly into Cortex Opportunity Manager and Backhaul Booster

PCS Software Integrates Triumph Market Rate Intelligence Directly into Cortex Opportunity Manager and Backhaul Booster PCS Software Integrates Triumph Market Rate Intelligence Directly into Cortex Opportunity Manager and Backhaul Booster PR Newswire HOUSTON, June 16, 2026 Carriers now have access...

Triumph Financial TFIN Q1 2026 Earnings Transcript

@media (max-width: 768px) {
 .image-container {
 width: 100% !important;
 float: none !important;
 margin: 0 0 1rem 0 !important;
 }
 }

Image source: The Mo...

Triumph Announces Dividend for 7.125% Series C Fixed-Rate Non-Cumulative Perpetual Preferred Stock

Triumph (the Company) (NYSE: TFIN) today announced that the Companys Board of Directors declared a quarterly cash dividend of $17.81 per share on its 7.125% Series C Fixed-Rate Non-Cumulative Perpetual Preferred Stock, represented by depositary shares (NYSE: TFIN-PR), each representing a 1/40th...

Noteworthy Thursday Option Activity: TFIN, BTU, SOLS

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Triumph Financial Inc (Symbol: TFIN), where a total volume of 2,186 contracts has been traded thus far today, a contract volume which is representative of approx...

Triumph Financial, Inc. (NYSE:TFIN) Given Average Rating of "Hold" by Analysts

Shares of Triumph Financial, Inc. (NYSE:TFIN - Get Free Report) have earned a consensus recommendation of "Hold" from the six brokerages that are presently covering the company, Marketbeat.com...

M&T Bank Corp Has $2.55 Million Position in Triumph Financial, Inc. $TFIN

M&T Bank Corp increased its position in shares of Triumph Financial, Inc. (NYSE:TFIN - Free Report) by 235.5% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 40,628 shares of the company's stock after purchasing...

Triumph Financial Q1 Earnings Call Highlights

Triumph Financial (NYSE:TFIN) executives struck an upbeat tone on the company's first-quarter earnings call, pointing to improving performance in its transportation-focused businesses and early signs...

Triumph Financial (NYSE:TFIN) Shares Gap Up - Should You Buy?

Triumph Financial (NYSE:TFIN) Shares Gap Up - Here's What Happened...

Triumph Financial's (TFIN) "Neutral" Rating Reiterated at DA Davidson

DA Davidson reaffirmed a "neutral" rating and issued a $60.00 target price on shares of Triumph Financial in a research note on Wednesday...

Triumph Financial (NYSE:TFIN) Shares Down 4.8% - Should You Sell?

Triumph Financial (NYSE:TFIN) Trading Down 4.8% - Time to Sell...

Triumph Financial, Inc. is a holding company, which engages in offering traditional banking and financial solutions. It operates through the following segments: Banking, Factoring, Payments, Intelligence, and Corporate. The Banking segment relates to traditional banking services. The Factoring segment includes the operations of Triumph Business Capital, which offers factoring services. The Payments segment offers a payment network for the over-the-road trucking industry. The Corporate segment refers to financing, investment activities, management, and administrative expenses. The company was founded by Aaron P. Graft on November 10, 2003, and is headquartered in Dallas, TX.

Triumph Financial Inc

Neutral Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$76.81
Prev Close	$76.77
Open	$77.13
Dividend Yield	0.00%
50-Day Moving Average	$68.69
Beta	1.31
Avg. Volume	240,652.99
PE Ratio	64.53

52-Week High	$77.90
52-Week Low	$46.43
Market Capitalization	$1.83B
EPS (Annual)	$0.929
Price to Book	2.02
Revenue Per Employee	$347,578.62

Feed

News

Sentiment

Earnings

Fundamentals

Info

TFINTriumph Financial Inc

Latest TFIN News